Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Key Inclusion Criteria: * Written informed consent or assent * Confirmed diagnosis of CF * History of chronic infection with Pseudomonas aeruginosa * Sputum culture positive for Pseudomonas aeruginosa at Screening * FEV1 ≥ 25% of predicted value at Screening Key Exclusion Criteria: * FEV1 \<25% of predicted at Screening * History of major complications of lung disease within 8 weeks prior to Screening * Hemoptysis of ≥60 mL in a 24-hour period within 4 weeks prior to Screening * History of positive culture for Burkholderia cepacia within 2 years prior to Screening * History of pulmonary tuberculosis or non-tuberculous mycobacterial lung disease treated within 2 years prior to Screening or requiring treatment at the time of screening * History of Allergic Broncho-Pulmonary Aspergillosis or any other condition requiring systemic steroids at a dose ≥ equivalent of 10 mg/day of prednisone within 3 months prior to Screening * Presence of any clinically significant cardiac disease * History of lung transplantation * Daily, continuous oxygen supplementation or nighttime supplemental oxygen requirement of greater than 2 L/min * Administration of any investigational products within 8 weeks prior to study Day 1 * Smoking tobacco or any substance within 6 months prior to screening or anticipated inability to refrain from smoking throughout the study